Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-II, a Formulation manufacturing
facility, of Eugia Pharma Specialities Ltd., a wholly owned subsidiary of the Company, situated at Bhiwadi, Alwar, Rajasthan, from 25 April to 03 May 2024.
The inspection closed with 7 observations. The observations are procedural in nature and will be responded to within the stipulated time.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
